CA1275928C - Suppression of withdrawal symptoms in opioid-induced tolerance or dependence - Google Patents

Suppression of withdrawal symptoms in opioid-induced tolerance or dependence

Info

Publication number
CA1275928C
CA1275928C CA000508574A CA508574A CA1275928C CA 1275928 C CA1275928 C CA 1275928C CA 000508574 A CA000508574 A CA 000508574A CA 508574 A CA508574 A CA 508574A CA 1275928 C CA1275928 C CA 1275928C
Authority
CA
Canada
Prior art keywords
calcium channel
channel blocking
pharmaceutical composition
blocking drug
opioid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000508574A
Other languages
English (en)
French (fr)
Inventor
Esam E. El-Fakahany
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Application granted granted Critical
Publication of CA1275928C publication Critical patent/CA1275928C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA000508574A 1985-05-13 1986-05-07 Suppression of withdrawal symptoms in opioid-induced tolerance or dependence Expired - Lifetime CA1275928C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73366485A 1985-05-13 1985-05-13
US733,664 1985-05-13

Publications (1)

Publication Number Publication Date
CA1275928C true CA1275928C (en) 1990-11-06

Family

ID=24948609

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000508574A Expired - Lifetime CA1275928C (en) 1985-05-13 1986-05-07 Suppression of withdrawal symptoms in opioid-induced tolerance or dependence

Country Status (6)

Country Link
US (1) US4797410A (de)
EP (1) EP0204951B1 (de)
JP (1) JPS61260025A (de)
AT (1) ATE84713T1 (de)
CA (1) CA1275928C (de)
DE (1) DE3687541T2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806277A1 (de) * 1988-02-27 1989-09-07 Troponwerke Gmbh & Co Kg Verwendung von 1,4-dihydropyridin-derivaten
WO1990011074A1 (en) * 1989-03-22 1990-10-04 Pang Peter K T Parathyroid hypertensive factor
US5886012A (en) * 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
CA2016465A1 (en) * 1989-06-02 1990-12-02 Zola Phillip Horovitz Method for preventing or treating anxiety employing a calcium channel blocker
US5124340A (en) * 1989-06-28 1992-06-23 The United States Of America As Represented By The Department Of Health And Human Services Use of calcium channel blocker to prevent ***e induced craving and reinforcement
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
DE69722191T2 (de) * 1996-03-08 2004-04-01 Nycomed Danmark Aps Dosiszusammensetzung mit modifizierter freigabe aus vielen einzelkomponenten
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
BRPI0015284B8 (pt) 1999-10-29 2021-05-25 Euro Celtique S/A formulações de hidrocodona de liberação controlada
GB0019055D0 (en) * 2000-08-03 2000-09-27 Unilever Plc Antiperspirant and deodorant products and methods for their use
KR101045144B1 (ko) 2000-10-30 2011-06-30 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CA2671197A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
US20170071879A1 (en) * 2015-09-15 2017-03-16 Alexandre Vamvakides Prototypical analgesic profile of 3,3-diphenyl-n-(1-phenylethyl)propan-1-amine (fendiline)
GR1009145B (el) * 2016-08-10 2017-10-20 Αλεξανδρος Δημητριου Βαμβακιδης Πρωτοτυπη αναλγητικη δραση της 3,3-διφαινυλο-ν-(1-φαινυλαιθυλ) προπαν-1-αμινη (fendiline)

Also Published As

Publication number Publication date
EP0204951A2 (de) 1986-12-17
JPH0584287B2 (de) 1993-12-01
EP0204951A3 (en) 1990-05-30
JPS61260025A (ja) 1986-11-18
DE3687541T2 (de) 1993-05-13
DE3687541D1 (de) 1993-03-04
ATE84713T1 (de) 1993-02-15
US4797410A (en) 1989-01-10
EP0204951B1 (de) 1993-01-20

Similar Documents

Publication Publication Date Title
CA1275928C (en) Suppression of withdrawal symptoms in opioid-induced tolerance or dependence
US3966940A (en) Analgetic compositions
Martin History and development of mixed opioid agonists, partial agonists and antagonists.
US4315936A (en) Analgesic composition
US20060167032A1 (en) Pharmaceutical composition and method for treating disorders of the central nervous system
EP0270290A3 (de) Methode und Präparate zur Reduzierung neurotoxischer Schäden
AU2003210486A1 (en) Pharmaceutical composition and method for treating disorders of the central nervous system
EP0932416A2 (de) Verfahren und potenzierte zusammensetzung zur behandlung von migräne
WO2004000354A2 (en) Method of treating the syndrome of lipodystrophy
WO2001052851A1 (en) Methods for the treatment of substance abuse
JP2003520234A (ja) 薬物中毒の治療方法
EP0514023B1 (de) Verwendung Glycine/NMDA-Rezeptorliganden zur Herstellung eines Arzneimittels zur Behandlung von Drogenabhängigkeit und Entzugserscheinungen
WO1992014464A1 (en) Use of sigma receptor antagonists for treatment of ***e abuse
EP0844241B1 (de) Inhibitor des erwerbs der abhängigkeit/resistenz gegen betäaubende analgetika
Ronai et al. Orientation of the oxygen atom at C-6 as a determinant of agonistic activity in the oxymorphone series.
CA1322523C (en) Central nervous system injury treatment with opiate- receptor antagonists
US5025018A (en) Central nervous system injury treatment with opiate-receptor antagonist
EP0013110B1 (de) Analgetikum
NZ206121A (en) Analgesic compositions containing alpha-methyl-4-(2-thienylcarbonyl)-benzene-acetic acid
Maxwell et al. Naloxone
Sophronov et al. Nifedipine but not verapamil inhibits subjective effects of iv morphine in opiate‐dependent patients
McMillan et al. Effects of N‐substituted analogs of (−)‐α‐acetylmethadol and (−)‐α‐methadol on schedule‐controlled behavior
Cowan et al. An In Vivo Pharmacological Analysis of Benzomorphan Binding Sites in Rats
AU2001226574A1 (en) Methods for the treatment of substance abuse
EP0480458A2 (de) Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend Viminol zur Behandlung von Drogenabhängigkeit

Legal Events

Date Code Title Description
MKEX Expiry
MKEX Expiry

Effective date: 20071106